Heart failure & cardiomyopathiesResearch article
Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines
- State-of-the-art review
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF); HF drugs approved by the US FDA
Main finding
As reported in the abstract
FDA-approved HF drugs and mortality effect
- Drugs approved for HFrEF in the last decade
- 6
- HFrEF drugs of the last decade that reduced mortality (sacubitril/valsartan, PARADIGM-HF; dapagliflozin, DAPA-HF)
- 2
- Drugs approved for HFpEF in the last decade
- 3
- HFpEF-approved drugs that reduced mortality
- 0
- Drugs approved for chronic stable HFrEF before 2015 (all reduced mortality and morbidity except digoxin, which only reduced HF hospitalization)
- 11
- Drugs approved for HFpEF before 2015
- 0
Further findings
HFpEF trials meeting their primary endpoint, under review for approval
- Trials (finerenone FINEARTS-HF; semaglutide STEP-HFpEF/DM ×2; tirzepatide SUMMIT)
- 4
Original publication
Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines. J Am Coll Cardiol. Published 26 August 2025. doi:10.1016/j.jacc.2025.06.036
Summarised from the published abstract; every number is checked against it